🇺🇸 FDA
Patent

US 7348429

Process for purifying N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide(zaleplon) and crystalline forms of zaleplon accessible with the process

granted A61PA61P25/20

Quick answer

US patent 7348429 (Process for purifying N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide(zaleplon) and crystalline forms of zaleplon accessible with the process) held by TEVA Gyógyszergyár Zártkörüen Müködö Részvénytárasaság expires Mon Mar 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA Gyógyszergyár Zártkörüen Müködö Részvénytárasaság
Grant date
Tue Mar 25 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61P, A61P25/20